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Estrogen receptor-alpha (ER), encoded by the ESR1 gene located on 6q25, is a nuclear 
transcription factor. Since it was reported in 2007 that more than 20% of breast cancers 
show ESR1 gene amplification, there has been considerable controversy about its 
frequency and clinical significance. The aim of this study was to assess the real and 
exact frequency and levels of ESR1 amplification in breast cancers. In a total of 106 
breast needle biopsy specimens examined by immunohistochemistry, 78 tumors 
contained more than 10% ER-positive cancer cells. In fluorescence in situ 
hybridization (FISH) analysis with an ESR1-specific probe, variously extended ESR1 
signals were found in ER-expressing cells. Some of these were indistinguishable from 
large clustered signals generally accepted to mean high-level gene amplification in 
homogeneously staining regions (HSR), and could be considered to represent gene 
amplification. However, with RNase treatment, the ‘HSR-like’ signals changed to small 
compact signals, and are thus thought to represent concentrated RNA. FISH using two 
differently labeled probes corresponding to the non-overlapping 5' and 3'-end portions 
of the ESR1 gene on imprinted cells showed a preserved spatial relationship of the 3’ to 
5’ sequence of ESR1, therefore strongly suggesting that the RNA consisted of primary 
transcripts. Using imprinted cells obtained by 51 fresh tumors, precise enumeration of 
ESR1 signals with a correction by the number of centromere 6 on FISH after RNase A 
treatment revealed that three tumors (5.9%) had tumor cells with one to three additional 
copies of ESR1 as predominant subpopulations. This infrequent and low level of gene 
amplification of ESR1 was also detected as a ‘gain’ of the gene by analysis with 
multiplex ligation-dependent probe amplification (MLPA). We believe that these 
consistent results from immunohistochemistry, FISH, and MLPA in the present study 
















Estrogen receptor-alpha (ER) is as a nuclear transcription factor activated by 
estrogen to regulate the growth and differentiation of normal breast epithelial cells. 
These pathways remain operative to varying degrees in breast cancers, and thus ER is 
a target for various endocrine therapies [1, 2]. ER is encoded by the estrogen 
receptor-alpha gene (ESR1) located on 6q25. In 2007, Holst et al. [3] reported that more 
than 20% of breast cancers showed ESR1 gene amplification, mainly based on FISH 
results using tissue microarrays. Furthermore, they suggested that the amplification of 
ESR1 is a frequent mechanism for ER overexpression, and that the amplification was 
significantly correlated to the response to anti-estrogen therapy. However, this was 
immediately disputed by other groups of researchers, because first, other FISH and 
chromogen in situ hybridization (CISH) studies using tissue microarrays [4, 5] detected 
amplification in less than 1.5% of breast cancers, and second, DNA extraction methods 
such as array comparative genomic hybridization (CGH) and quantitative PCR 
consistently detected very low frequencies (less than 3%) or no amplification [4, 6, 7]. 
Since then, there has been heated discussion about the frequency and clinical 
significance of ESR1 amplification [8-10]. Recently, Moelans et al. also examined ESR1 
amplification of breast carcinomas using multiplex ligation-dependent probe 
amplification (MLPA), and found that its amplification is rare and has poor concordance 
with the amplification detected by FISH and overexpression of ER [11]. 
The major cause of the discordance between FISH and CISH studies might be the use 
of different (an automated or manual) scoring systems and/or different interpretations of 
the definition of ‘amplification’. The used samples also could be another cause, because 
tissue microarrays used in previous FISH studies were made from isolated surgical 
specimens in which the size of each specimen was too small to observe background 
lesions or possible cancer heterogeneity. Furthermore, it is technically difficult to 
optimize FISH conditions for each specimen in an array [5], and after the introduction 
of neo-adjuvant therapy, surgical materials may have therapeutic effects. MLPA is a new, 
high-resolution method for detecting copy number variations in genomic sequences [12]. 
Moelans et al. have shown high concordance between the ERBB2 status of breast 
cancers detected by MLPA, CGH, FISH, and immunohistochemistry (IHC) [13]. Thus, 
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in the present study, we performed FISH using whole sections of core needle biopsy 
specimens that were carefully fixed and processed to optimize FISH results, as well as 
imprinted cells obtained from fresh surgical specimens. In addition, we analyzed gene 
amplification by MLPA and compared the results with FISH results. In order to test the 




Materials and Methods 
Core needle biopsies, touch smears, and DNA samples 
Core needle biopsy specimens obtained from 106 breast carcinomas were 
immediately fixed in 10% buffered formalin for no longer than overnight and embedded 
in paraffin according to standard procedures. Serial sections (4 μm) placed onto 
MAS-coated glass slidesTM (Matsunami, Tokyo, Japan) were used for 
hematoxylin-eosin staining, IHC detection of ER and ERBB2, and FISH analysis. The 
tumors consisted of 14 ductal carcinomas in situ, 87 invasive ductal carcinomas, and 5 
invasive lobular carcinomas. Two patients had bilateral cancers. From surgery on 49 
patients, small fragments of cancer tissue (51) and adjacent non-neoplastic tissues (37) 
were trimmed. The cancer tissues were touched on MAS-coated slidesTM, which were 
dried and fixed immediately in metacarn solution (methanol/acetic acid, 3:1) and stored 
in a freezer until FISH analysis. From the rest of the fresh samples, high molecular 
weight DNA was prepared by protease K (Boehringer Mannheim, Mannheim, 
Germany) digestion and phenol/chloroform extraction as described elsewhere [14] and 
used for MLPA analysis. This laboratory study was approved by the Institutional 
Review Board at the Kanazawa University Hospital (Approval No. 181), and written 
informed consent was obtained from all patients. 
 
Cell lines and normal lymphocytes 
The breast cancer cell line MCF-7 expressing ER, and cell lines UACC-812 and 
MDA-361 that do not express ER [15], were obtained from the American Type Culture 
Collection (Rockville, MD, USA). Cell lines were grown in RPMI supplemented with 
10% fetal bovine serum. The cells were fixed in metacarn solution and dropped on 
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MAS-coated slidesTM. Metaphase spreads of normal lymphocytes were purchased from 
Abbott Laboratories (Abbott Park, IL, USA). 
 
IHC 
Monoclonal antibodies against human ER (clone 6F11, Novocastra, Newcastle upon 
Tyne, UK; working dilution of 1:50), and a polyclonal antibody against the internal 
domain of the human ERBB2 (Nichirei, Tokyo, Japan; dilution, 1:100) were used. 
Antibodies were visualized by avidin-biotin binding to peroxidase-conjugated 
secondary antibodies (DAKO A/S, Glostrup, Denmark). For evaluations of 
ER-staining, only nuclear immunostaining significantly higher than that of stromal 
cells was considered as positive. ER positivity was defined as 10% or more positively 
stained cells per 10 high-power fields according to the recommendation by the Eighth 
Annual International Expert Consensus Panel on the primary therapy for early cancer in 
St. Gallen, Switzerland [16]. For the evaluation of ERBB2 positivity, each tumor was 
scored using the four-tier system recommended by the American Society of Clinical 
Oncology (ASCO) for IHC of ERBB2 [17] and reviewed by two of the authors. 
FISH 
We performed FISH analysis of gene amplification of ESR1 on core needle biopsies, 
imprinted cancer cells, and cultured cells using ESR1-specific bacterial artificial 
chromosomal (BAC) probe RP11-450E24, which was the same probe used by Holst et 
al. [3] by labeling with SpectrumOrangeTM (Abbott). In order to standardize the 
chromosome number, a SpectrumGreenTM-labeled pericentromeric probe (CEP6TM, 
Abbott), which was specific to centromere 6, was cohybridized. 
Tumors with 2+ or 3+ staining by IHC examination of ERBB2 were also further 
analyzed for ERBB2 amplification by FISH. This was done using the 
SpectrumOrangeTM-labeled ERBB2 locus (17q12) specific probe, RP11-62N23, and the 
SpectrumGreenTM-labeled pericentromeric 17 probe (CEP17TM, Abbott). BAC probes 
were acquired from BACPAC Resources (Oakland, CA, USA). Our FISH probes 
contained E. coli tRNA in addition to human placental DNA, and Cot-1 DNA as a 
competitor nucleic acid sequence. 
First, we performed FISH using formalin-fixed paraffin-embedded (FFPE) tissues and 
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imprinted cells with standard methods as described elsewhere [18] without using RNase 
A digestion. The FISH protocols for imprinted cancer and cultured cells were the same 
as for FFPE tissues, except protein digestion was made by 0.25 mg/ml pepsin at 37°C 
for 10 min, and prehybridization fixation was by 1% formaldehyde at room temperature 
for 5 min. Second, FISH with RNase A treatment was performed by incubating slides 
with RNase A (100 micro g/ml in 2XSSC) at 37°C for 30 min before hybridization. 
When necessary, imprinted cells or tissue sections were submitted to digestion with 
RNase A or with 1U/ml of DNase I for 10 min at 37°C after the first standard FISH 
[19]. 
The specimens were counterstained with 4’,6-diamidine-2’-phenylindole 
dihydrochloride and p-phenylenediamine in phosphate-buffered saline and glycerol 
(DAPI IITM) (Abbott) and examined under a fluorescence microscope (Olympus, Tokyo, 
Japan) equipped with a Triple Bandpass FilterTM set and single Bandpass FilterTM sets 
(Abbott) to discriminate DAPI II, SpectrumOrangeTM, and SpectrumGreenTM. FISH 
results were scored manually and gene amplification was determined according to the 
American Society of Clinical Oncology (ASCO)-approved criteria of ERBB2 
amplification: gene signals/centromere signals > 2.2, definite; 1.8-2.2, equivocal [17]. 
In addition, gene signals arranged in aggregates, a characteristic of amplified genes 
located in homogeneous staining regions (HSR) of a chromosome (‘HSR-type’ signals), 
as discussed later, were interpreted as positive for amplification. All FISH analyses were 
performed with observers blinded to the results of the IHC and MLPA analyses. FISH 





MLPA analysis was performed using a kit (SALSA MLPA KIT P078-B1 Breast 
Tumour) from MRC-Holland (Amsterdam, The Netherlands). This kit contains 39 
probes for 10 different genes, including two probes for ESR1 and four probes for 
ERBB2. In addition, 11 reference probes are included in this probe mix, detecting 11 
different autosomal chromosomal locations that are relatively quiet in breast tumors. 
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The MLPA PCR products were separated on an ABI-310 capillary sequencer (Applied 
Biosystems, Foster City, CA, USA) and interpreted using Genmapper software (Applied 
Biosystems). Data analysis was performed with Coffalyser MLPA-DAT software 
(version 9.4, MRC-Holland) generating normalized peak values. Peak values below 0.7 
were defined as lost, between 0.7 and 1.3 as normal, between 1.3 and 2.0 as gain, and 






  Seventy-eight of a total of 106 cases (74%) were ER-positive, and 28 (26%) cases 
were negative. The populations of positive cells in each tumor were more than 80% in 
64 tumors and 10-80% in 14 tumors. There were no significant differences between the 
positive frequencies of DCIS (71%, 10/14), IDC (75%, 65/87), and ILC (60%, 3/5). In 
non-cancerous breast tissues, ER staining was found heterogeneously in ductal and 
acinal cells ranging from 2 to 30%. ERBB2 overexpression was found in 27 tumors (12 




  The RP11-450E24 probe detected its target focus as symmetrical double red spots on 
chromosome 6 in metaphase chromosomes of normal lymphocytes (Figure 1A). Most 
interphase nuclei of MCF-7 had four centromere 6-specific signals, indicating tetrasomy 
6, and those of UACC-812 and MDA-361 had three signals, indicating trisomy 6 
(Figures 1B-D). Usually, orange ESR1 signals are smaller than the green centromeric 6 
signals in UACC-812, MDA-361, and normal lymphocytes; however, nuclei of MCF-7 
showed one or two large extended signals of RP11-450E24 corresponding to 
“HSR-type” signals, suggesting gene amplification in HSR [21, 22], although HSR was 
not found in metaphase spreads (Figure 1E). 
  FISH analysis of FFPE tumors revealed one to approximately six large extended 
ESR1 signals closely associated with smaller centromere 6 signals in all ER-positive 
tumors except one. The sizes of the large signals varied, continuously ranging from the 
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largest one indistinguishable from “HSR type” signals found ERBB2-amplified cancer 
cells as found in Case 1 (Figure 2A), to those slightly larger than centromere 6 signals. 
The comparison of adjacent sections alternatively used for FISH and IHC frequently 
showed that the brightness of the fluorescence signal of ESR1 was correlated to the 
immunohistochemical intensity of ER, almost on a nucleus-by-nucleus basis (Figures 
2B-E). This correlation was found not only in ER-positive cancer cells, but also 
ER-positive non-neoplastic mammary epithelial cells (Figure 2F and G). In the 28 
tumors without ER expression, no large extended signals of ESR1 were found (Figure 
2H). 
In FISH analysis on touch smears from 51 tumors consisting of 38 ER-positive 
tumors and 13 negative tumors, large extended signals were exclusively found in 
ER-positive tumors (Figures 3A and B); however, generally, their numbers in each 
tumor decreased with the increase of compact ESR1 signals compared to FISH on FFPE 
tissues. 
 
DNase I & RNase A treatments 
The tight correlation of the extended signal and ER expression prompted us to test 
whether the large extended signals of the ESR1 gene represented DNA-RNA 
hybridization. After finishing standard FISH and confirming the ‘HSR-type’ signals, 
cover slips were removed and the sections were treated with DNase I or RNase A. With 
RNase A treatment, the sizes of the HSR-type signals became much smaller (Figures 3B 
and C). When DNase I treatment was performed instead of RNase A, although 
centromere-specific signals were breached, the extended HSR1 signals were unchanged 
(Figure 3D). Thus, it is most likely that the extended signals of ESR1 represent nuclear 
RNA, probably together with its gene. 
We further analyzed whether it is possible to visualize processing events along this 
gene by FISH, and to estimate the three-dimensional structure of this nuclear RNA. This 
was done by dual-color FISH using SpectrumGreenTM-labeled RP11-450E24 and 
SpectrumOrangeTM-labeled RP11-54K4. The latter covers the 3'-end portion of ESR1 
from 166 bases downstream of RP11-450E24. The precise locations of the probes' 
targets are shown in Figure 4A with references to the UCSC Genome Browser [23] and 
the Ensemble Genome Browser [24]. As a result, dual-color FISH showed that two large 
spots of the different fluorescences were found abutting each other. Even when they 
were coalesced, the two RNA accumulations remained as separate signals and did not 
intermingle as shown in Figure 4D. 
Then, we repeated the FISH on all needle biopsies and touch smears with incubation 
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by RNase A before hybridization. The results showed that the extended signals of ESR1 
disappeared, and all ESR1 signals were compact signals smaller than centromere 6, both 
in biopsy specimens and imprinted cells as shown in Figure 5. We counted copy 
numbers of ESR1 and centromere 6 and calculated the ratio of ESR1 signals/centromere 
6 signals (amplification ratio) for approximately 40 nuclei per tumor specimen. In 
needle biopsies of the 106 tumors, two tumors had an amplification ratio of 2.4, which 
meets the ASCO criterion of ERBB2 amplification. The FISH of imprinted cells 
revealed that each tumor was composed of several fractions with different 
ESR1/centromere 6 signal patterns as shown in Figure 5C. The ESR1/centromere 6 
signal patterns found in more than 40% of cancer nuclei were considered as 
predominant subpopulations and are shown in Table 1. The amplification ratios detected 
for biopsy specimens of the 51 cases in which both FISH on FFPE tissues and FISH on 
imprinted cells were performed are also shown in Table 1. Three tumors (Cases 1-3) had 
predominant subpopulations of cancer cells with an additional one to three ESR1 signals 
as shown in Figure 5B; thus, they were considered to be tumors with low-level 
amplifications. However, in two of the three (Cases 2 and 3) this low-level amplification 
was not detected by FISH on the biopsy specimens as shown by the amplification ratios 
of 1.5 and 1.6, respectively. 
 
RP11-62N23 / CEP17TM 
Gene amplification of ERBB2 was found in 20 cases (18.9%): all 15 of the 3+ tumors 
and five of 12 of the 2+ tumors. The 13 cases showed the “HSR type” of ERBB2 signals, 
and seven had amplification ratios > 2.2, and one tumor (Case 2) showed unequivocal 
amplification with a ratio of 2.1. Although RNase A treatment altered the ESR1 signals 
considerably, it did not change the FISH results of ERBB2 as shown in Figure 6. 
When ERBB2 positive tumors are defined according to ASCO as those with IHC 3+ 
staining and/or ERBB2 gene amplification by FISH, the ERBB2 positivity was 
negatively correlated with ER overexpression at a statistically significant level (five of 
80 versus 15 of 26) (2 = 33.9, p = 0.00). 
 
MLPA analysis 
MLPA analysis was successful in all 51 tumors in which fresh surgical materials were 
obtained. The respective means of the two ESR1 peak values and four ERBB2 peak 
values were calculated and are shown in Table 1 with the results of the FISH and IHC of 
ER and ERBB2. No ESR1 ‘amplified’ tumors (peak value > 2.0) were found, although 
a ‘gain’ of ESR1 was found in five tumors (Cases 1-5). The three tumors with the 
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highest peak values (Cases 1-3) were those exhibiting low-level amplification by FISH 
on imprinted cells. However, two of the three did not meet the ASCO-approved criteria 
of HER2 amplification, which is “the ratio of gene signals per the centromeric signals > 
2.2”. ERBB2 ‘amplification’ was found in six (Cases 9, 27, 33, 34, 41, and 48 in Table 
1) by MLPA, and all of them also showed gene amplification by FISH. Among the five 
tumors with a ‘gain’ in MLPA (Cases 1, 2, 6, 10, and 31), the one with the highest value 






Gene amplification in small chromosomal regions may appear cytogenetically as 
HSR and is recognized as a clustered signal in interphase FISH. Conversely, a clustered 
arrangement of gene signals observed in interphase FISH indicates gene amplification 
in HSRs; thus, we and others suggest that it should be called “HSR-type” and that it be 
considered a criterion of gene amplification in FISH analysis of ERBB2 status [3, 21, 
22]. In the present FISH study, variously extended ESR1 signals were found in 
ER-expressing cells. Some of them were indistinguishable from ‘HSR-type’ signals of 
ERBB2 found in breast cancers, and could be considered to represent gene amplification 
in HSRs. In fact, in previous studies reporting that gene amplification of ESR1 occurs in 
more than 20% of breast cancers, these FISH images seem to be the basis for their high 
reported frequencies [3, 8]. However, the present study showed that this ‘HSR-like’ 
signal is RNase A-sensitive and DNase I-resistant; thus, the hybridization partner 
proved to be RNA. 
Concentrations of nuclear RNAs are found by FISH at the transcription sites of such 
actively transcribed genes as collagen type 1, [25, 26],-actin [27], and dystrophine 
[28], and are studied in normal and mutant cells to discern the interrelationship of RNA 
metabolism and nuclear structure [25, 26]. At the present time, two possibilities that are 
not mutually exclusive explain nuclear RNAs found by FISH: one is that mRNA forms 
a “track” that moves away from the gene [26], and the other is that nascent transcripts 
are attached to the gene-like “trees” [28]. In this respect, our FISH results using two 
differently labeled probes corresponding to the non-overlapping 5' and 3'-end portions 
of the ESR1 gene are very informative, because the two fluorescences representing two 
portions were not mixed, but were found abutting each other. If the accumulated RNAs 
were mature mRNAs, then due to their much reduced sizes (less than one forty-fifth) 
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compared to that of the gene, the signals would have been much weaker, and 
furthermore, the assembly of molecules containing two portions simultaneously would 
have made the two color signals intermingle as depicted in Figure 4A. Therefore, our 
results strongly suggest that the RNA represents newly synthesized nascent RNA 
molecules extending from the gene as depicted in Figure 4B. It is also possible that this 
RNA is derived from another gene being transcribed in the opposite direction. For 
example, it is known that a stable transcript produced from NCYM, MYCN anti-sense 
DNA, is cotranscribed with MYCN [29]. By searching databases, we found a 258-base 
transcript [30] that is located on the opposite DNA strand of ESR1. However, it is not 
possible that this small transcript caused the HSR-like signals found in this study. 
Unfortunately, FISH analysis using clinical specimens does not have high enough 
resolving power to further clarify the molecular kinetic events. Smith et al. reported that 
simultaneous hybridization of differently labeled probes for different non-overlapping 
sequences within the dystrophine gene, as in our experiment, produced non-overlapping 
fluorescences in a single-molecular FISH study [28]. They explained the result by 
‘cotranscriptional splicing’, that is, more 5’ introns are spliced out of the nascent RNA 
molecules before the 3’ end of the RNA is transcribed; thus, the two sequences of the 
transcript do not exist simultaneously. In any case, there was a positive correlation 
between ER-overexpression detected by IHC and the amount of this nuclear RNA 
detected by FISH on a nucleus-by-nucleus basis. Thus, this protein overexpression is 
thought to come from active RNA transcription from ESR1 genes, which occurs by a 
different mechanism than gene amplification. 
RNA is most vulnerable to degradation during the usual process of making 
pathological specimens from surgical materials. In fact, in standard protocols of FISH 
using FFPE tissues, RNase treatment is not mandatory [31] and is only recommended to 
reduce background RNA staining in FISH using cultured cells [32]. The core needle 
biopsies used in the present study minimized the duration of pre-fixative steps, and thus 
may preserve RNA well. FISH on touch smear specimens had fewer extended signals 
than those found in FFPE tissues in several cases. This is well explained by the fact that 
the metacarn fixative does not preserve RNA well [33]. However, in spite of being 
similarly prepared, and the supposedly active RNA transcription, transcripts of ERBB2 
were not detected in ERBB2-overexpressing cells. Therefore, RNA retention probably 
depends on the properties of individual transcripts [33, 34]. In fact, in our previous 
DNA-DNA FISH studies targeting EGFR, ERBB2, and MYC, etc., we have never found 




When the results of MLPA and two FISH analyses were compared, a gain of ESR1 
was found in five tumors by MLPA (Cases 1-5), and the FISH using imprinted cells 
revealed that three (Cases 1-3) had additional copies of ESR1, which were evaluated to 
be low-level amplification. FISH on FFPE tissues, however, could not detect this 
low-level amplification in two of them (Cases 2 and 3). This is because FISH on 
imprinted cells, different from FISH on FFPE tissues, had no effects on nuclear 
truncation, and thus more precise enumeration of the signals is possible. The sensitivity 
and specificity of the ‘gain’ by MLPA against amplification detected by FISH using 
imprinted cells, if the present cut-off value of 1.3 is used, are 100% and 96%, 
respectively, and both would be 100% if a cut-off value of 1.4 is used. 
In the analysis of ERBB2, the six tumors with the highest peak values (Cases 9, 27, 
33, 34, 41, and 48) were those with high-level amplification in FISH using FFPE tissues. 
Both the sensitivity and specificity of MLPA against FISH were 100%. Thus, MLPA is a 
useful tool to detect gene amplification of ESR1 and ERBB2, especially when an 
appropriate cut-off value is chosen. Moelans et al. performed MLPA for 135 breast 
cancers using the same kit and the same analysis software as in the present study, but 
with DNAs extracted from FEPE tissues, and found gene amplification of ESR1 in three 
(2%) with marginal peak values of no more than 2.1 and a gain in 8 (6%) [11]. We do 
not consider our ESR1 gain rate of 5.9% (3/51) to be fundamentally different from the 
frequency of Moelans et al. This low-level amplification was not correlated with ER 
overexpression, which mostly occurs by a different mechanism than gene amplification. 
Consequently, the consistent results of IHC, FISH, and MLPA in the present study 
show that the amplification of ESR1 in breast carcinoma occurs as low-level 
amplification, and in addition, at a low frequency of 5.9%. We believe that the results in 
our present study settle the long-standing debate concerning gene amplification of ESR1 





We gratefully acknowledge helpful discussions with Dr. Shin-ichi Horike, Frontier 
Science Organization, Institute for Gene Research, Kanazawa University; and with Dr. 
Takeo Kubota, Department of Epigenetic Medicine, University of Yamanashi. 
This work was financially supported by the Japanese Ministry of Education, Sports, 
Science and Culture Nos. C22590310 (A. O.) and C23590409 (Y.D), and The Smoking 





Statement of author contributions 
AO, MI, JI, YD conceived and designed the work. AO, SH, SK, HI, HK, and RT 
carried out experiments and analyzed data. All authors were involved in writing the 








Dual-color FISH using an ESR1-specific probe (RP11-450E24, orange fluorescence) 
and centromere 6-specific probe (green fluorescence) on metaphase spreads of normal 
bone marrow cells (A) and MCF-7 (E), and interphase nuclei of MCF-7 (B), UACC-812 
(C), and MDA-361 (D). 
 
Fig. 2 
Dual-color FISH using an ESR1-specific probe (RP11-450E24, orange fluorescence) 
and centromere 6-specific probe (green fluorescence) (A, C, E, G, and H) and IHC for 
ER (B, D, and F) on formalin-fixed paraffin-embedded tumors. B and C, D and E, and 
F and G are adjacent sections alternatively used for FISH and IHC. The same nuclei are 
denoted by arrows in B and C. The regions within the black rectangle in panels D and F 
correspond to the fields in panels E and G, respectively. Large ‘HSR-like’ signals were 
found in cancer nuclei in A (Case 1), C, and E, and nuclei of ductal epithelia in G. 
ER-negative cancer cells have small contracted signals (H). 
 
Fig. 3 
Dual-color FISH using an ESR1-specific probe (RP11-450E24, orange fluorescence) 
and centromere 6-specific probe (green fluorescence) on touch smears from Case 1 (A) 
and Case 10 (B-D). Most ESR1 signals were ‘HSR-like’ (A and B). By RNase 
A-treatment, the ESR1-signals became faint; however, centromere 6 signals were 
unchanged (C). By DNA-1 treatment, the ESR1-signals were unchanged; however, 
centromere 6 signals disappeared (D). Panels B and C show the same imprinted cells 





Dual-color FISH on imprinted cells using RP11-450E24 (green fluorescence) and 
RP11-54K4 (orange fluorescence) corresponding to the non-overlapping 5'- and 3'-end 
portion of ESR1, respectively. The precise locations of the probe targets are shown in A, 
where italic figures represent chromosome position according to the UCSC Genome 
Browser [23]. The information for the ESR1 transcript was obtained from the Ensemble 
database [24]. The result showed two large spotty signals fused or tightly apposed (D). 
B and C are two possible molecular events explaining Panel D. Model B shows nascent 
transcripts extending from the gene. The 5’-end portion may undergo 
post-transcriptional splicing. Model C shows mRNAs. The real sequence size of the 
mRNA is one forty-fifth that of the primary transcript in full-length. Closed circles, 
dotted lines, and solid lines represent exons and transcripts with and without splicing. 




Dual-color FISH using an ESR1-specific probe (RP11-450E24, orange fluorescence) 
and centromere 6-specific probe (green fluorescence) after RNase A treatment on a 
biopsy specimen (A, Case 1) and imprinted cells (B, Case 1; C, Case 10). HSR-like 





FISH using an ERBB2-specific probe (orange fluorescence) and centromere 17-specific 
probe (green fluorescence) without (A) and with (B) RNase A treatment. The ‘HSR-like’ 
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